Condition: Invasive Fungal Disease · Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium · Sponsor: Assistance Publique - Hôpitaux de Paris
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.
This description comes directly from the study's public registry record.
Alexandra SERRIS, MD, PhD · 06 68 80 24 92 · alexandra.serris@aphp.fr
Gael PLASTOW, Project advisor · 01 44 38 18 57 · gael.plastow@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Necker Enfants Malades | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06285188